Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho

Mizuho initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research report sent to investors on Monday morning, Marketbeat reports. The firm issued an outperform rating and a $14.00 target price on the stock.

Several other equities analysts also recently issued reports on IMMX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Immix Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.00.

Immix Biopharma Trading Down 4.7%

IMMX traded down $0.30 on Monday, reaching $6.12. The stock had a trading volume of 200,386 shares, compared to its average volume of 939,503. Immix Biopharma has a 12-month low of $1.34 and a 12-month high of $7.73. The business’s 50-day moving average price is $5.55 and its two-hundred day moving average price is $3.76. The company has a market cap of $324.17 million, a P/E ratio of -7.95 and a beta of 0.31.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Friday, November 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). As a group, analysts predict that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Allworth Financial LP purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $30,000. Velan Capital Investment Management LP purchased a new position in Immix Biopharma during the second quarter worth approximately $52,000. Mathes Company Inc. acquired a new position in Immix Biopharma during the fourth quarter worth $56,000. Tocqueville Asset Management L.P. grew its holdings in Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after buying an additional 10,950 shares in the last quarter. Finally, Imprint Wealth LLC acquired a new stake in shares of Immix Biopharma in the 3rd quarter worth $141,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.